Skip to main content
OpenTrials
Completed

NCT Number: NCT02367261

A Multi-center Study to Evaluate Bone Loss, Survival Rate and Stability of SPI Implant

The current prospective clinical study's aim is to determine ABT's SPI implant survival rate, crestal interproximal bone resorption during 24 months post implant insertion and to assimilate the drilling sequence during the clinical use of SPI implants.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

West China Hospital of Stomatology, Chengdu, Sichuan, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men and women over the age of 18 years who need implantation of 1-4 implants.
  • Patients who are able to understand the requirements of the study, and are willing and able to comply with its instructions and schedules.
  • Patients who had provided written informed consent to participate in the study prior to any study procedure.
  • Patients in general good health in the opinion of the principal investigator as determined by medical history and oral examination.

Exclusion criteria

  • Immediate loaded implants.
  • Patient requiring bone augmentation
  • Treatment with anticoagulant drugs (INR under 1.8) or bisphosphonates.
  • Treatment with anticonvulsants drugs.
  • Untreated Periodontal disease and inability of the patient to maintain reasonable oral hygiene according to study requirements.
  • Patients with history of alcohol, narcotics or drug abuse.
  • Patients under steroid therapy.
  • Patients receiving radiotherapy, chemotherapy or any other immunosuppressive treatment or who have been administered radiotherapy in the last 5 years.

Patients through at anytime received radiotherapy to the head and neck region will be excluded anyway.

  • Metabolic bone disorders and/or bone augmentation.
  • Uncontrolled bleeding disorders such as: hemophilia, thrombocytopenia, granulocytopenia.
  • Degenerative diseases.
  • Osteoradionecrosis.
  • Renal failure.
  • Organ transplant recipients.
  • HIV positive.
  • Malignant diseases.
  • Diseases that compromise the immune system.
  • Unbalanced diabetes mellitus. (HbA1c above 6.5)
  • Psychotic diseases.
  • Hypersensitivity to one of the components of the implant in general and titanium in particular.
  • Women who are pregnant or lactating.
  • Lack of patient cooperation.
  • Uncontrolled endocrine diseases.
  • Any systemic condition that is unbalanced and therefore precludes surgical procedures.
  • Parafunctional habits.- e.g Bruxism.
  • Temporomandibular joint disease.
  • Various pathologies of the oral mucosa for example: Benign mucous pemphigoid, desquamative ginigivitis, erosive lichen planus ,malignancy of oral cavity, bolus erosive diseases of the oral mucosa.
  • Flapless procedures.

-

Treatment and study plan

SPI implant

Device

SPI implant - the original spiral implant

Primary outcomes

  1. Cumulative Survival Rate

    Time frame: 24 months

Sponsors and collaborators

Lead sponsor

Alpha - Bio Tec Ltd.

Industry

Registry information

Official study title

An Open, Prospective, Multi-center Study to Evaluate Bone Loss, the Survival Rate of SPI Implant System and Implant Stability Over a 24 Months, in Patients With Tooth Loss Requiring up to 4 Implants, in Staged Loading Protocol.

Acronym: SPI

Important dates

Study start
2014
Primary completion
2017
Study completion
2017
First posted
Feb 20, 2015
Registry last updated
Jun 28, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.